GREY:DGCRF - Post by User
Post by
ready2go1on Jul 30, 2009 11:32am
229 Views
Post# 16178550
The Buzz
The Buzz Its interesting to speak with Gen-Probe investors and hear their response when asked; what excites you about this company? The discussion quickly goes to the start of their FDA trial for their new prostate cancer marker. There is never a mention of Diagnocure, but they go on to rattle off why Gen-Probe will corner this market.
I did have a chance some time ago to sit down and speak with a U.S. analyst who covers gpro and all he talked about was how important PCA3 was to their potential growth. I asked him what would be his price target for gpro with an FDA approved prostate cancer marker and I also asked him what he thought it would do for Diagnocure. He looked at me and said that I don't cover that company but their gain would be 10-fold.
It would be nice to hear some news tonight during their call but either way we are close to hearing that the trial has started and at some point the share price should respond to being the first company out there to have a new marker to test for prostate cancer. I have read countless of articles in the past several weeks that discuss the pitfalls of psa. Now is the time. Lets get it on!